Skip to main content

Table 1 Population characteristics and clonidine concentration at steady state

From: Clonidine in the treatment of adolescent chronic fatigue syndrome: a pilot study for the NorCAPITAL trial

Number (male/female) 5 (3/2)
  Median (range)
Age (years) 14
  (14–19)
BMI (kg/m2) 20.8
  (17.0-22.4)
Disease duration (months) 34
  (27–48)
C0 of clonidine (μg/L), 0.21
  (0.18-0.36)
Cmax of clonidine (μg/L) 0.41
  (0.38-0.56)